Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $74.17 Consensus PT from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $74.1667.

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Truist Financial reaffirmed a “hold” rating and issued a $61.00 price target (down previously from $63.00) on shares of Lantheus in a report on Monday, November 10th. TD Cowen reduced their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. B. Riley cut their target price on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Finally, Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th.

Lantheus Trading Up 2.3%

Lantheus stock opened at $63.30 on Friday. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The stock has a market cap of $4.20 billion, a P/E ratio of 26.60 and a beta of -0.10. The company’s fifty day simple moving average is $55.50 and its 200-day simple moving average is $63.43.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. As a group, sell-side analysts forecast that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Trading of Lantheus

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after buying an additional 115,338 shares in the last quarter. Reinhart Partners LLC. grew its stake in shares of Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after purchasing an additional 197,719 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 2.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock valued at $134,534,000 after purchasing an additional 31,454 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Lantheus in the 3rd quarter worth approximately $65,654,000. Finally, Swedbank AB lifted its holdings in Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.